Core Viewpoint - Rongchang Biologics (688331.SH) is expected to achieve a net profit of approximately 716 million yuan in 2025, marking a significant turnaround from a net loss of 1.468 billion yuan in 2024, indicating a maturation from reliance on single-event drivers to a more diversified competitive strength [3][4] Financial Performance - The company anticipates a revenue of approximately 3.25 billion yuan for 2025, representing an increase of about 1.53314 billion yuan or 89% compared to the previous year [3] - The expected net profit of 716 million yuan for 2025 contrasts sharply with the previous year's net loss of 1.468 billion yuan, showcasing a healthy revenue structure [3][4] Growth Drivers - The growth in performance is primarily attributed to rapid sales growth of core products, Taitasip and Vidisicimab, which have become the main engines of revenue [4] - The company has successfully established a significant partnership with Vor Biopharma Inc., granting exclusive global development and commercialization rights for Taitasip outside Greater China, leading to a substantial increase in technology licensing revenue [4] Innovation and Development - Rongchang Biologics is focused on innovative products that are first-in-class (FIC) or best-in-class (BIC), with ongoing clinical trials for new indications of its core products [5] - The company showcased its four advanced technology platforms at the JPM 2026 conference, which include target discovery, antibody discovery, protein engineering, and ADC technology platforms, indicating a robust early-stage R&D pipeline [6] Strategic Collaborations - The company has formed deep collaborations with international partners such as Pfizer, Santen, and Vor Bio, enhancing its innovation value [6] - A recent deal with AbbVie for a PD1/VEGF dual antibody has been valued at 5.6 billion USD, marking a strong start to business development transactions in 2026 [6]

智通财经APP讯，康隆达(603665.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利 润为8000万元到1.2亿元，与上年同期(法定披露数据)相比，将实现扭亏为盈。 ...

证券日报网讯1月29日，广宇集团（002133）发布公告称，公司预计2025年度归属于上市公司股东的净 利润盈利3，000.00万元至4，500.00万元，上年同期亏损100，897.50万元，实现扭亏为盈。 ...

此外，商务拓展（BD）收入增长也是诺诚健华2025年营业收入快速增长的另一个重要因素。2025年， 诺诚健华持续推进全球化进程，全年达成两项BD交易。2025年1月，诺诚健华与Prolium Bioscience Inc. 关于CD20×CD3双特异性抗体ICP-B02 （CM355）达成许可合作。2025年10月，诺诚健华与Zenas BioPharma, Inc.达成关于奥布替尼及两项临床前分子相关权益的授权许可协议。（王珞） 诺诚健华1月29日发布2025年年度业绩预告。公告显示，诺诚健华预计2025年实现营收23.65亿元，与上 年同期相比增长约134%。与此同时，公司预计2025年首次实现扭亏为盈，归母净利润为6.3亿元左右， 较上年同期归母净利润增加约10.74亿元。 转自：中国证券报·中证网 2025年，诺诚健华药品收入持续快速增长。2025年4月，奥布替尼获批新适应症，用于一线治疗慢性淋 巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）成人患者。除奥布替尼外，2025年5月，坦昔妥单抗 联合来那度胺治疗不适合ASCT条件的复发/难治性弥漫性大B细胞淋巴瘤（r/r DLBCL）成人患者的上市 ...

智通财经APP讯，东方甄选(01797)发布截至2025年11月30日止6个月业绩，该集团期内取得总营收23.12 亿元人民币，同比增加5.7%;公司拥有人应占溢利2.39亿元，同比扭亏为盈;每股基本盈利0.23元。 ...

Core Viewpoint - Beijing Resources (00618) experienced a significant stock price increase of over 32%, reaching HKD 0.242, with a trading volume of HKD 2.5709 million following the release of its interim results for the six months ending September 30, 2025 [1] Financial Performance - The company reported revenue of RMB 807 million, reflecting a year-on-year growth of 8.05% [1] - Profit attributable to shareholders turned positive at RMB 1.875 billion, compared to a loss in the previous period [1] - Basic earnings per share were reported at 68.50 cents [1] Revenue Drivers - The increase in revenue was primarily driven by the e-commerce and distribution business, which contributed approximately RMB 116 million due to the addition of new e-commerce platforms and product lines [1] - There was a slight increase in revenue from property investment and management, amounting to approximately RMB 3.476 million [1]

Core Viewpoint - Coastal Home reported significant financial improvement for the six months ending September 30, 2025, with a substantial increase in revenue and a shift from loss to profit [1][2] Financial Performance - Revenue for the period was approximately HKD 34.9 million, representing an increase of about 20.8 times compared to the same period last year [1] - The profit attributable to the company's owners for the period was approximately HKD 16.7 million, a turnaround from a loss of approximately HKD 36.9 million in the same period last year [1] - Basic earnings per share for the period were 4.04 HKD cents, compared to a loss of 8.90 HKD cents per share in the previous year [2] Debt and Equity - As of September 30, 2025, the net debt to total equity ratio was 48%, down from 58% on March 31, 2025 [1] Property Sales and Rental Income - Confirmed sales revenue from property sales was HKD 34.7 million, with no sales revenue recorded in the same period last year, primarily from the sale of the Shenzhen Nord Financial Center, which accounted for 100% of property sales revenue [1] - Rental income from properties decreased from HKD 1.6 million in the previous year to HKD 0.2 million, mainly due to the sale of the Shenzhen Nord Financial Center [1] Investment Performance - The property investment segment recorded a loss of HKD 0.8 million for the period, an improvement from a loss of HKD 2.3 million in the same period last year [1]

Group 1 - The core viewpoint of the article is that宏基集团控股 (01718) reported a revenue of HKD 187 million for the six months ending September 30, 2025, representing a year-on-year increase of 4.6% [1] - The company recorded a profit attributable to owners of HKD 1.08 million, a significant turnaround from a loss of HKD 10.56 million in the same period last year [1] - Earnings per share were reported at HKD 0.005 [1] Group 2 - Revenue from foundation engineering increased approximately 30.5% from about HKD 119 million for the six months ending September 30, 2024, to about HKD 156 million during the reporting period [1] - The increase in revenue was primarily due to the company undertaking a large foundation engineering project during the reporting period [1]

Core Viewpoint -宏基集团控股 reported a revenue of HKD 187 million for the six months ending September 30, 2025, representing a year-on-year increase of 4.6% and a turnaround to a profit of HKD 1.08 million from a loss of HKD 10.56 million in the same period last year, with earnings per share at HKD 0.005 [1] Group 1: Financial Performance - The company achieved a revenue of HKD 187 million, up 4.6% year-on-year [1] - The profit attributable to owners was HKD 1.08 million, compared to a loss of HKD 10.56 million in the previous year [1] - Earnings per share were reported at HKD 0.005 [1] Group 2: Segment Performance - Revenue from foundation engineering increased approximately 30.5% from about HKD 119 million for the six months ending September 30, 2024, to about HKD 156 million during the reporting period [1] - The increase in foundation engineering revenue was primarily due to the undertaking of a large foundation engineering project during the reporting period [1]

Core Viewpoint - North China Resources (00618) reported a revenue of 807 million yuan for the six months ending September 30, 2025, representing a year-on-year increase of 8.05% [1] Financial Performance - The company achieved a profit attributable to shareholders of 1.875 billion yuan, marking a turnaround from a loss in the previous period [1] - Basic earnings per share were reported at 68.50 cents [1] Revenue Drivers - The increase in revenue was primarily driven by the e-commerce and distribution business, which contributed an additional 116 million yuan due to new e-commerce platforms and product lines [1] - There was a slight increase in revenue from property investment and management, amounting to approximately 3.476 million yuan [1]